Fig. 1.

Dipeptide concentrations (fmol/µl) in CSF (A) and plasma (B) of 43 CSF samples from children with neurological or metabolic conditions of unknown origin. In CSF, out of 43 patients, anserine was detectably in 24 patients, Gly-Asp in 43, Carnosine in 4, γ-Glu-ε-Lys in 36, Asp-Gln in 26, Gly-Pro in 43, Glu-Ser in 21, Ser-Gln in 17, Ala-Glu in 43, Pro-Gly in 42, Gly-Glu in 23, Ala-Ala in 24, Ser-Ala in 13, Glu-Glu in 21, Gly-Phe in 3, Val-Tyr in 22, Phe-Ala in 3 and Leu-Pro in 13. In plasma, anserine was detectably in 12 patients, Gly-Asp in 43, Carnosine in 12, γ-Glu-ε-Lys in 3, Asp-Gln in 14, Gly-Pro in 42, Glu-Ser in 25, Ser-Gln in 17, Ala-Glu in 42, Pro-Gly in 39, Gly-Glu in 37, Ala-Ala in 28, Ser-Ala in 23, Glu-Glu in 37, Gly-Phe in 9, Val-Tyr in 21, Phe-Ala in 15, Ala-Gly in 27, Ala-Pro in 24 and Ala-Phe in 1. Displayed is a Tukey-Box-Plot